
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has concluded that a booster dose of Moderna’s COVID-19 vaccine can be administered in persons 18 years of age and older.
This decision is based on data showing that a third dose of this vaccine administered 6 to 8 months after the second dose causes an increase in antibody levels in adults whose antibody levels were declining. The booster dose consists of half the dose used for the primary vaccination schedule.
Current data indicate that the pattern of side effects after the booster is “similar to that after the second dose.” The risk of inflammatory heart conditions or other very rare side effects after the booster dose “is being carefully monitored.”
At the national level, public health agencies may issue official recommendations on the use of booster doses, taking into account the local epidemiological situation, as well as emerging efficacy data and limited booster dose safety data.
Earlier this month, the CHMP concluded that a booster dose of the BioNTech/Pfizer vaccine can be administered at least 6 months after the second dose in persons 18 years of age and older. In addition, it recommended that an additional dose of Pfizer and Moderna be given to people with severely weakened immune systems at least 28 days after their second dose.
“This recommendation is supported by clinical evidence that a 50 ug booster dose induces a strong immune response against COVID-19. We thank the EMA and the CHMP for their review. We believe that mRNA vaccines are well positioned to adapt to the evolving epidemiology of SARS-CoV-2. We are grateful for the opportunity to provide individuals in the EU with another layer of protection,” commented Moderna’s CEO Stéphane Bancel.
